Brief: Spagopix Says Phase I Study To Next Dose Level And Expansion To Additional Site

Spago Nanomedical AB (publ)

24/03/2020 24:29

March 23 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.TE :
    * SPAGOPIX PHASE I STUDY TO NEXT DOSE LEVEL AND EXPANSION TO
ADDITIONAL SITE
    * SPAGO NANOMEDICAL AB (PUBL) - DATA FROM FIRST DOSE GROUP
IN
PHASE I TRIAL SHOW THAT SN132D IS WELL TOLERATED
    * SPAGO NANOMEDICAL AB (PUBL) - ISRC FURTHER CONCLUDE THAT
SN132D
DOSE SHOULD BE INCREASED IN ORDER TO OPTIMIZE CONTRAST
ENHANCEMENT OF TUMORS
    * SPAGO NANOMEDICAL AB (PUBL) - DECIDED TO EXPAND SN132D
STUDY TO
ADDITIONAL BREAST CANCER CENTER, SAHLGRENSKA UNIVERSITY HOSPITAL

Source text for Eikon:  ID:nWkr2BGgd2 
Further company coverage:  SPAGO.TE 

 ((Reuters.Briefs@thomsonreuters.com;))